Boston Advisors’s Coherus Oncology CHRS Stock Holding History

Boston Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.24M	Buy	61,106 +23,179	+61%	+$463K	0.06%	354
2019 Q2	$838K	Sell	37,927 -21,238	-36%	-$369K	0.04%	397
2019 Q1	$807K	Buy	59,165 +26,105	+79%	+$348K	0.04%	381
2018 Q4	$299K	Buy	33,060 +3,725	+13%	+$43.1K	0.02%	536
2018 Q3	$484K	Sell	29,335 -180	-0.6%	-$3.19K	0.02%	485
2018 Q2	$413K	Buy	+29,515	New	+$422K	0.01%	527
2017 Q3	–	Sell	-16,995	Closed	-$244K	–	647
2017 Q2	$244K	Buy	+16,995	New	+$327K	0.01%	607

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Boston Advisors's CHRS Position: Q3 2019 in Review

Boston Advisors increased its Coherus Oncology (CHRS) stake by 61% in Q3 2019, buying an estimated $463K and bringing the position to 61,106 shares worth $1.24M. The position accounts for 0.06% of the portfolio, ranked #354.

Boston Advisors first reported a position in CHRS in Q2 2017 and has held it in 7 quarters since. 167 funds tracked by Wall St. Rank hold CHRS as of Q3 2019.

Boston Advisors held 61,106 shares of Coherus Oncology worth $1.24M as of Q3 2019.
Boston Advisors bought 23,179 Coherus Oncology shares in Q3 2019, an estimated $463K.
Coherus Oncology made up 0.06% of Boston Advisors's portfolio in Q3 2019, its #354 holding.
Boston Advisors first reported a position in Coherus Oncology in Q2 2017 and has held it in 7 quarters since.
167 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.